253 related articles for article (PubMed ID: 21621406)
1. Loss of lamin A/C expression in stage II and III colon cancer is associated with disease recurrence.
Belt EJ; Fijneman RJ; van den Berg EG; Bril H; Delis-van Diemen PM; Tijssen M; van Essen HF; de Lange-de Klerk ES; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Eur J Cancer; 2011 Aug; 47(12):1837-45. PubMed ID: 21621406
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
4. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
[TBL] [Abstract][Full Text] [Related]
7. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.
de Weger VA; Turksma AW; Voorham QJ; Euler Z; Bril H; van den Eertwegh AJ; Bloemena E; Pinedo HM; Vermorken JB; van Tinteren H; Meijer GA; Hooijberg E
Clin Cancer Res; 2012 Feb; 18(3):882-9. PubMed ID: 22156611
[TBL] [Abstract][Full Text] [Related]
8. Tumor budding as an index to identify high-risk patients with stage II colon cancer.
Nakamura T; Mitomi H; Kanazawa H; Ohkura Y; Watanabe M
Dis Colon Rectum; 2008 May; 51(5):568-72. PubMed ID: 18286339
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas.
Li M; Li JY; Zhao AL; Gu J
Oncology; 2007; 73(1-2):52-7. PubMed ID: 18334831
[TBL] [Abstract][Full Text] [Related]
10. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients.
Meng WJ; Sun XF; Tian C; Wang L; Yu YY; Zhou B; Gu J; Xia QJ; Li Y; Wang R; Zheng XL; Zhou ZG
Oncology; 2007; 72(1-2):82-8. PubMed ID: 18004081
[TBL] [Abstract][Full Text] [Related]
12. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.
O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ
J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725
[TBL] [Abstract][Full Text] [Related]
13. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer.
Hong SP; Min BS; Kim TI; Cheon JH; Kim NK; Kim H; Kim WH
Eur J Cancer; 2012 May; 48(8):1235-43. PubMed ID: 22071131
[TBL] [Abstract][Full Text] [Related]
14. Low microsatellite instability is associated with poor prognosis in stage C colon cancer.
Kohonen-Corish MR; Daniel JJ; Chan C; Lin BP; Kwun SY; Dent OF; Dhillon VS; Trent RJ; Chapuis PH; Bokey EL
J Clin Oncol; 2005 Apr; 23(10):2318-24. PubMed ID: 15800322
[TBL] [Abstract][Full Text] [Related]
15. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
[TBL] [Abstract][Full Text] [Related]
16. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q.
Sarli L; Bottarelli L; Bader G; Iusco D; Pizzi S; Costi R; D'Adda T; Bertolani M; Roncoroni L; Bordi C
Dis Colon Rectum; 2004 Sep; 47(9):1467-82. PubMed ID: 15486743
[TBL] [Abstract][Full Text] [Related]
17. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer.
Poincloux L; Durando X; Seitz JF; Thivat E; Bardou VJ; Giovannini MH; Parriaux D; Barriere N; Giovannini M; Delpero JR; Monges G
Surg Oncol; 2009 Dec; 18(4):357-65. PubMed ID: 19027288
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population.
Deschoolmeester V; Van Damme N; Baay M; Claes K; Van Marck E; Baert FJ; Wuyts W; Cabooter M; Weyler J; Vermeulen P; Lardon F; Vermorken JB; Peeters M
Eur J Cancer; 2008 Oct; 44(15):2288-95. PubMed ID: 18707864
[TBL] [Abstract][Full Text] [Related]
19. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
20. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
